Will GlaxoSmithKline plc’s Vaccine Stop Ebola?

GlaxoSmithKline plc (LON: GSK) is leading the charge to find a way to stop the spread of Ebola.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline plc (LSE: GSK) is leading the race to try and find a vaccine that will stop the advance of the deadly Ebola virus, which is currently spreading across West Africa. 

According to the World Health Organization, since March the deadly virus has killed 1,552 people. And it’s believed that this figure will grow significantly during the next few months. 

So, there is an urgent need for an effective Ebola vaccine and governments around the world have been rushing to find one, before the situation gets really out of hand. The US National Institutes of Health, or NIH for short, is one of the world’s foremost medical research centres and is currently developing a vaccine with Glaxo. 

Good progress gsk

So far, progress has been good, with an experimental vaccine performing extremely well in primate studies. Human studies are commencing as we speak and Glaxo should have results by the end of 2014. However, the vaccine will not be ready for use until the middle of 2015, after Glaxo has had enough time to thoroughly test and manufacture the product to the correct standards.

Glaxo became involved in the Ebola vaccine after buying Swiss vaccine company Okairos AG in 2013. Okairos had been working on the vaccine with the NIH since 2011, although Ebola is was such a rare disease that there was no rush to get the vaccine on the production line. 

But now Glaxo and NIH are throwing their combined weight behind the vaccine, to try and stop this deadly disease as quickly as possible.

Attractive qualities 

Glaxo has many more attractive qualities aside from its ground-breaking Ebola vaccine. Actually, the company’s involvement in helping discover a vaccine for Ebola really backs up the Glaxo investment thesis. 

You see, while Glaxo’s shares have been sold off during the past 12 months, due to concerns about penalties stemming from bribery allegations, Glaxo remains at the forefront of the world’s health industry.

Indeed, aside from the Ebola vaccine, Glaxo has more than 40 potentially lifesaving treatments underdevelopment. And that’s not to mention the Glaxo products that are already being sold to customers. 

All in all, as Glaxo is a key part of the world’s health infrastructure, the company is highly defensive and would fit well into any portfolio.

Low valuation

Nevertheless, Glaxo’s defensive nature means that investors are willing to pay a premium to get their hands on the company’s shares. For example, Glaxo’s shares currently trade at a forward P/E of 15.3. City analysts expect Glaxo’s earnings to expand 6% next year, which puts shares on a 2015 P/E of 14.5.

While this valuation may seem high for some, Glaxo is cheap compared to many of its pharmaceutical sector peers — many of Glaxo’s international peers trade at a forward P/E of around 28.

Glaxo is also a great pick for dividend hunters. The company supports a dividend yield of 5.3% at current levels, and City analysts expect Glaxo’s yield to hit 5.5% next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »